Abstract Number: 2561 • ACR Convergence 2023
The Prognostic Value of the “2022 ACR/EULAR Classification Criteria for Giant Cell Arteritis”: Data from the Italian Society of Rheumatology Vasculitis Study Group
Background/Purpose: The 2022 classification criteria for giant cell arteritis (GCA) have been recently published. The aim of this study is to investigate whether the score…Abstract Number: 0044 • ACR Convergence 2023
Aberrant Mevalonate Metabolite Farnesyl Pyrophosphate-Induced Neutrophil Hyperactivation in Behçet’s Disease Pathogenesis
Background/Purpose: Behçet’s disease (BD) is a chronic vasculitis characterized by polymorphonuclear neutrophils (PMNs) hyperactivation with unknown etiology. The over-productions of neutrophil extracellular traps (NETs) and…Abstract Number: 0697 • ACR Convergence 2023
Alterations in Composition and Function of Gut Microbiota in Patients with Large-Vessel Vasculitis
Background/Purpose: The gut microbiome has a critical role in immune homeostasis and there is growing interest in understanding the relationship between the microbiome and autoimmunity.…Abstract Number: 0747 • ACR Convergence 2023
Clinical Phenotype of Patients with Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica
Background/Purpose: It has been reported that more than a quarter of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). It remains unclear…Abstract Number: 1538 • ACR Convergence 2023
Large Vessel Involvement in Antineutrophil Cytoplasmic Antibody- Associated Vasculitis: A Single Center Experience over Two Decades
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is currently categorized under the small vessel vasculitides and includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA),…Abstract Number: 1573 • ACR Convergence 2023
Inpatient Prevalence and Comorbidity of Takayasu’s Arteritis: Nationwide Inpatient Sample 2016-2020
Background/Purpose: Takayasu’s Arteritis (TAK) is a granulomatous large-vessel vasculitis that affects the aorta and its branches, and it is more commonly observed in women. We…Abstract Number: 2381 • ACR Convergence 2023
ANCA-associated Vasculitis and Renal Disease in a Multidisciplinary Outpatient Clinic in Northern Spain
Background/Purpose: The severity of clinical features and outcomes in previous series of patients reported with renal disease related to ANCA-associated vasculitis (AAV) vary greatly, probably…Abstract Number: 2415 • ACR Convergence 2023
Giant Cell Arteritis Is Associated with Worse Hospital Outcomes in Aortic Aneurysm/Dissection Hospitalizations: A Nationwide United States Population-Based Study
Background/Purpose: Giant Cell Arteritis (GCA) is a known risk factor for Aortic Aneurysm/Dissection (AAD). However, it is unclear if patients with GCA have worse hospital…Abstract Number: 2562 • ACR Convergence 2023
Immune Checkpoint Inhibitors-Induced Large Vessel Vasculitis: Data from a Multicenter Study
Background/Purpose: Immune checkpoint inhibitors (ICIs) have dramatically improved the prognosis for many cancers. The therapeutic effect of ICIs is based on their ability to release…Abstract Number: 031 • 2023 Pediatric Rheumatology Symposium
Multisystem Inflammatory Syndrome in Children Phenotypes Vary Between SARS-CoV-2 Variants
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a serious complication associated with COVID-19, presenting as a hyperinflammatory disorder characterized by fever and multiorgan dysfunction.…Abstract Number: 045 • 2023 Pediatric Rheumatology Symposium
Patient Reported Outcomes in Pediatric Vasculitis
Background/Purpose: Vasculitis is a group of multisystem, often relapsing diseases that can affect patients through disease activity, damage, and treatment toxicity. Vasculitis in adults often…Abstract Number: 060 • 2023 Pediatric Rheumatology Symposium
Are the Levels of Cytokines Good Biomarkers for Smoldering Disease Activity in Childhood-Takayasu Arteritis?
Background/Purpose: Biomarkers for disease activity in adult Takayasu arteritis (TA) have been studied exhaustively, but there are inconsistencies among the studies (1). Childhood-TA (c-TA) differs…Abstract Number: 061 • 2023 Pediatric Rheumatology Symposium
Variation in Treatment Approaches to IVIG- Refractory Kawasaki Disease (KD) Among Pediatric Rheumatologists: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Treatment of Refractory KD Survey
Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in children in North America. Initial treatment with IVIG has significantly reduced the…Abstract Number: 071 • 2023 Pediatric Rheumatology Symposium
Clinical Manifestations and Management of Takayasu Arteritis: A Single Center Pediatric Cohort
Background/Purpose: Takayasu arteritis (TA) is a rare granulomatous vasculitis that affects large vessels, including the aorta, its major branches, and the pulmonary artery. Data on…Abstract Number: L17 • ACR Convergence 2022
Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis
Background/Purpose: Immunosuppression in Takayasu Arteritis (TA) reduces the risk of arterial damage and disease progression. However, long-term use of glucocorticoids (GC) and other immunosuppressants carries…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 41
- Next Page »